In a report published Monday, Morgan Stanley analyst Steve Beuchaw initiated coverage on Myriad Genetics MYGN with an Underweight rating and $25.00 price target.
In the report, Morgan Stanley noted, “We forecast 28% share loss and 42% price declines by '17 in the BRCA franchise, which accounts for ~95% of GP. Pipeline tests have lower margins and long timelines. Consensus EPS for '16 appears 15% high; PT $25.”
Myriad Genetics closed on Friday at $34.89.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in